Results(4978)
Valproate: survey on awareness of teratogenicity risk and impact of risk minimisation measures in women of childbearing age.
Belgium
EU PAS number:
EUPAS1000000735
First published:
03/11/2026
Study
Finalised
An Immuno-Dermatological disease registry to understand the burden of Atopic dermatitis (AD), Alopecia areata (AA), and Vitiligo in Indian Patients
India
EU PAS number:
EUPAS48566
First published:
03/11/2026
Study
Ongoing
“Palbociclib plus Aromatase- inhibitor as first-line treatment for Hormone Receptor (HR)-positive /Human Epidermal Growth Factor Receptor 2 (HER2)-negative locally advanced or metastatic breast cancer patients in Italy: a retrospective observational study (Palbo-Italy)”
Italy
EU PAS number:
EUPAS1000000352
First published:
03/11/2026
Study
Ongoing
Comparative Effectiveness of Roctavian to Standard of Care
Germany
EU PAS number:
EUPAS1000001075
First published:
03/11/2026
Study
Discontinued
Prospective, international, non-interventional study to assess the short- and long-term safety and effectiveness of adult patients with relapsed or refractory B cell acute lymphoblastic leukemia receiving Aucatzyl® treatment (AUTO1-LT2)
European Union
United Kingdom
United States
EU PAS number:
EUPAS1000001004
First published:
03/11/2026
Study
Planned
Real-world clinical outcomes, patient characteristics, and treatment patterns among patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-negative, claudin-18 isoform 2-positive gastric or gastroesophageal junction adenocarcinoma treated with zolbetuximab or other first line treatments: A cohort study using secondary data in Europe and Canada (RADIANCE)
Canada
France
Germany
Portugal
Spain
Sweden
EU PAS number:
EUPAS1000001120
First published:
03/11/2026
Study
Planned
A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources (COVID-19)
Italy
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS43556
First published:
03/11/2026
Study
Finalised
Enzalutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): A Non-Interventional Center-based Chart Review in Europe (ENHANCE)
France
Germany
EU PAS number:
EUPAS1000000776
First published:
03/11/2026
Study
Ongoing
Long-term safety after Holoclar® implant for restoration of corneal epithelium in patients with limbal stem cell deficiency due to ocular burns: observational study of routine clinical practice (HOLOSIGHT)
Austria
Belgium
Czechia
Denmark
France
Germany
Italy
Netherlands
United Kingdom
EU PAS number:
EUPAS10043
First published:
03/11/2026
Study
Ongoing
Incidence of selected adverse events in a population-based Danish cohort with atopic dermatitis treated with conventional systemic therapies: a matched case-cohort study.
Denmark
EU PAS number:
EUPAS1000000628
First published:
03/11/2026
Study
Ongoing
Non-interventional study of patients with Netherton Syndrome to characterise the natural history of disease (Natural history of Netherton Syndrome)
Austria
China
France
Germany
Italy
Japan
Netherlands
United Kingdom
United States
EU PAS number:
EUPAS103733
First published:
03/11/2026
Study
Discontinued
Early Experience with Etrasimod in Ulcerative Colitis Patients: an Observational Study in the United States
United States
EU PAS number:
EUPAS1000000587
First published:
03/11/2026
Study
Ongoing
An Active Surveillance Study to Monitor the Real-World Safety of Ritlecitinib Among Patients with Alopecia Areata in Denmark, France, and Sweden
Denmark
France
Sweden
EU PAS number:
EUPAS1000000512
First published:
02/11/2026
Study
Planned
Real-World Analysis of Exacerbations and Exacerbation-Related Costs Among Patients with Asthma Receiving Tezepelumab (CROSSROADS-5) (20240066)
United States
EU PAS number:
EUPAS1000000514
First published:
30/10/2026
Study
Ongoing
Nivolumab plus ipilimumab plus chemo vs pembrolizumab plus chemo in PD-L1 negative metastatic NSCLC patients: comparative effectiveness using the target trial emulation framework.
Netherlands
EU PAS number:
EUPAS1000001143
First published:
30/10/2026
Study
Planned
Administration of elranatamab in the real-world: Treatement patterns, healthcare resource utilization, costs, effectiveness, and safety (ALTITUDE)
United States
EU PAS number:
EUPAS1000000229
First published:
30/10/2026
Study
Finalised
Indirect treatment comparison of pegloticase in combination with methotrexate versus nanoencapsulated sirolimus plus pegadricase for the treatment of uncontrolled gout (20260129)
Other
EU PAS number:
EUPAS1000001127
First published:
30/10/2026
Study
Ongoing
European non-interventional post-authorization safety study (PASS) to evaluate cardiovascular (CV) events and all-cause mortality in patients newly exposed to abaloparatide or teriparatide
Germany
Spain
United Kingdom
United States
EU PAS number:
EUPAS1000000613
First published:
30/10/2026
Study
Planned
Patient characteristics, Adherence, and Clinical Outcomes among People Living with HIV (PLWH), Initiating Cabotegravir + Rilpivirine LA Regimen in the OPERA Cohort (216990)
United States
EU PAS number:
EUPAS1000000427
First published:
30/10/2026
Study
Ongoing
The persistence of vaccine-induced HBsAg-specific antibodies and immune memory in adults after complete primary vaccination with the GlaxoSmithKline (GSK) hexavalent Infanrix vaccine at infancy (HEP-IMMUNE)
Belgium
EU PAS number:
EUPAS1000001160
First published:
30/10/2026
Study
Ongoing
UpSwinG: Real World study on TKI activity in Uncommon mutations and Sequencing Giotrif®
Austria
China
France
Germany
Italy
Japan
Korea, Republic of
Spain
Taiwan
United Kingdom
EU PAS number:
EUPAS32098
First published:
30/10/2026
Study
Finalised
Understanding drug utilisation, treatment patterns, clinical outcomes, and profile of the patients receiving lutetium (177Lu) vipivotide tetraxetan for the treatment of metastatic prostate cancer: a multicountry, AI-powered registry (PULSE)
Canada
Germany
Italy
Portugal
Switzerland
EU PAS number:
EUPAS1000000935
First published:
30/10/2026
Study
Ongoing
Bias after censoring concomitant users of test- and control medication when investigating long-term survival outcomes in observational studies of medication effects
Germany
EU PAS number:
EUPAS1000001159
First published:
30/10/2026
Study
Planned
Retrospective analysis of adolescent patients suffering from hereditary angioedema treated with berotralstat in Europe: patients’ and treatment characteristics
Belgium
France
Germany
Italy
Portugal
Spain
United Kingdom
EU PAS number:
EUPAS1000000997
First published:
29/10/2026
Study
Planned
Real World Impact and Effectiveness of ABRYSVO Vaccination During Pregnancy Against RSV Illness in Infants (BERNI)
Argentina
Uruguay
EU PAS number:
EUPAS1000000224
First published:
29/10/2026
Study
Ongoing
QUVIVIQ® Pregnancy Registry (ID-078A403)
Canada
France
Germany
Italy
Spain
United Kingdom
United States
EU PAS number:
EUPAS1000000033
First published:
29/10/2026
Study
Discontinued
Brand-specific respiratory syncytial virus (RSV) vaccine effectiveness in Europe
Canada
Germany
Spain
United Kingdom
EU PAS number:
EUPAS1000000035
First published:
29/10/2026
Study
Ongoing
Long-term outcomes in patients treated with ADVAGRAF following standard criteria donor or expanded criteria donor kidney transplant in routine clinical practice in Europe: a multicenter secondary data (chart review) cohort study
France
Germany
Spain
EU PAS number:
EUPAS1000000589
First published:
29/10/2026
Study
Finalised
Safety of Paxlovid Among Patients with Moderate or Severe Hepatic or Renal Impairment
France
Spain
United Kingdom
EU PAS number:
EUPAS50123
First published:
29/10/2026
Study
Finalised
Safety of Paxlovid During Pregnancy
France
Spain
United Kingdom
EU PAS number:
EUPAS50117
First published:
29/10/2026
Study
Finalised
DARWIN EU® - Population demographics and disease frequency across the DARWIN EU® network
Belgium
Croatia
Estonia
France
Germany
Greece
Hungary
Netherlands
Norway
Portugal
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS1000000962
First published:
28/10/2026
Study
Ongoing
DARWIN EU® - Incidence rates of venous thromboembolic events in individuals with lung and ovarian cancers
Denmark
France
EU PAS number:
EUPAS1000001140
First published:
28/10/2026
Study
Ongoing
Post-authorisation Safety Study of Rimegepant in Patients with Migraine and History of Cardiovascular Disease in European Countries
Denmark
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS103990
First published:
28/10/2026
Study
Ongoing
European Cystic Fibrosis Society Patient Registry
Disease registry
Albania
Armenia
Austria
Belarus
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Georgia
Germany
Greece
Hungary
Iceland
Ireland
Israel
Italy
Latvia
Lithuania
Luxembourg
Moldova, Republic of
Montenegro
Netherlands
North Macedonia
Norway
Poland
Portugal
Romania
Russian Federation
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Türkiye
Ukraine
United Kingdom
First published:
27/10/2026
Data source
Human
Record completeness: 85%
Clinical and economic impact of 2nd line initiation of empagliflozin after metformin, as compared to 2nd line initiation of sulfonylurea after metformin in patients with type 2 diabetes and cardiovascular disease
United States
EU PAS number:
EUPAS43815
First published:
27/10/2026
Study
Cancelled
Comparing patient characteristics among populations with type 2 diabetes initiating liraglutide in European real-world data to the LEADER trial population: A descriptive study
Germany
Netherlands
Norway
United Kingdom
EU PAS number:
EUPAS1000001147
First published:
27/10/2026
Study
Planned
A non-interventional, real-world study of HRRm testing, treatment patterns, and overall survival among patients with metastatic castration-resistant prostate cancer initiating treatment with talazoparib plus enzaluatime in the US.
United States
EU PAS number:
EUPAS1000000963
First published:
27/10/2026
Study
Ongoing
Extended Cohort for E-health, Environment and DNA
Biobank
Primary care medical records
United Kingdom
First published:
26/10/2026
Data source
Human
Record completeness: 83%
Long term, prospective, observational cohort study evaluating the safety profile in patients with highly active relapsing multiple sclerosis (RMS) newly started on cladribine tablets − CLARION
Australia
Belgium
Canada
Croatia
Czechia
Denmark
Finland
Germany
Italy
Kuwait
Lebanon
Netherlands
Norway
Sweden
Switzerland
Türkiye
United States
EU PAS number:
EUPAS24484
First published:
26/10/2026
Study
Ongoing
Real-world identification, staging, monitoring, management, and progression in patients with metabolic dysfunction-associated steatohepatitis (MASH) across the fibrosis spectrum in EU4+UK: A retrospective multi-country chart review on compensated MASH cirrhosis (MASH-MAP)
France
Germany
Italy
Spain
United Kingdom
EU PAS number:
EUPAS1000001142
First published:
26/10/2026
Study
Planned
Compare data sources
Compare data sources